- Home
- SRPT
as 11-15-2024 4:00pm EST
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 12.2B | IPO Year: | 1997 |
| Target Price: | $182.00 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $78.67 - $173.25 | Next Earning Date: | 11-06-2024 |
| Revenue: | $1,640,348,000 | Revenue Growth: | 48.45% |
| Revenue Growth (this year): | 45.98% | Revenue Growth (next year): | 78.13% |
Stock Insider Trading Activity of Sarepta Therapeutics Inc. (DE) (SRPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Estepan Ian Michael | SRPT | Chief Financial Officer | Aug 30 '24 | Sell | $137.36 | 5,985 | $822,099.60 | 33,946 |
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now
Simply Wall St.
4 days ago
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem
Argus Research
5 days ago
SRPT: Lowering target price to $91.00
TipRanks
5 days ago
Sarepta recent weakness brings buying opportunity, says JPMorgan
TipRanks
9 days ago
Sarepta price target lowered to $193 from $200 at Baird
Zacks
10 days ago
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
MT Newswires
10 days ago
Cantor Fitzgerald Upgrades Sarepta Therapeutics to Overweight, $167 Price Target
BioPharma Dive
10 days ago
Sarepta scraps a Duchenne drug as gene therapy sales rise
Compare SRPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.